CAR-T Startup Gets €51M from Top&New Investors

21/03/2016 - 2 minutes

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe – and a new player in life science investment.

autolus_car-t_perceptive_biosciences_woodford

Autolus is a 1-year-old spin-off of the University College London (UCL) focusing on the development of next-generation CAR-T therapies, addressing current limitations of this ‘wonder therapy‘.

I tried figuring out what exactly Autolus is doing. It doesn’t disclose so much of its scientific strategy, but whatever the strategy is, it seems to have investors convinced. This Biopharma has now raised around €51.2M (£40M) in a series B round.

Part of the money comes from Woodford, arguably the most influential investor in European Life Sciences (and n°1 on our VC Top15).

Other investor is Perceptive Bioscience, its first investment since the opening of the fund in London last February. It is led by some key figures in the industry,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member